🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Palisade Bio, Inc. PALI PHARMA

Healthcare · Biotechnology · United States
https://www.palisadebio.com
Company Profile ↓
$2.20
+171.60% 1Y
Mkt Cap$383.40M
P/E3.38
P/B2.27
52W High$2.80
52W Low$0.54
Book Value$0.70
EPS (TTM)$0.65

Company Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 3.4, below the sector median of 24.8.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Growth & Price Performance

Stock Price Performance

1 Year:+171.60%
6 Months:+26.44%
3 Months:+26.44%
1 Month:+4.27%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 73% of range
$0.54 $2.80
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.88 · Neutral
Price Performance
1M+4.27%
3M+26.44%
6M+26.44%
1Y+171.60%
Valuation vs Sector

P/E of 3.38 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
3.38
Industry PE
24.83
Forward P/E
-7.86
PEG Ratio
-
Book Value
$0.70
Price to Book
2.27
P/S
554.18
EV/EBITDA
-4.30
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-13.92%
ROE
-51.37%
ROA
-32.98%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$0.65

Balance Sheet & Liquidity

Debt/Equity
0.05
Quick Ratio
23.96
Current Ratio
24.26
Debt
$0
Total Assets
$133.31M
Current Assets
$133.24M
Working Capital
$129.59M

Ownership

Promoter Holding
2.15%
Chg in Prom Hold
0.46%
FII / Inst Holding
101.26%
Chg in FII Hold
-0.23%

Financial Snapshot

Enterprise Value
$383.40M
Total Revenue (TTM)
$500.00K
EBITDA
$-35.35M
Free Cash Flow
$-8.65M
Operating Cash Flow
$-18.19M
Shares Outstanding
174.27M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PALI Palisade Bio, Inc. PHARMA 2.20 3.38 $383.40M 0.00% -13.92% -51.37% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------------000250.00K00-000-00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------2.31M2.84M2.92M9.98M10.75M
Operating Income -4.11M-4.64M-4.61M-4.99M-5.20M-4.35M-6.23M-3.83M-4.92M-4.23M-4.22M-2.59M-2.35M-2.02M-2.08M-2.46M-1.92M-2.12M-1.99M-1.84M-1.82M-1.95M-32.86M-3.02M-3.89M-3.57M-4.41M-2.53M-3.61M-3.78M--3.67M-4.21M-3.59M--2.31M-2.84M-2.92M-9.98M-10.75M
EBITDA ------------------------------------2.23M-2.78M-2.86M-8.90M-9.60M
Interest Expense -----------------------------------1.00K2.00K5.00K2.00K1.00K
Pretax Income ------------------------------------2.23M-2.78M-2.87M-8.90M-9.60M
Tax Provision ----------------------------------------
Net Income -4.46M-5.50M-5.05M-5.45M-5.64M-4.77M-6.61M-3.85M-5.22M-7.57M-4.65M-133.78K-2.15M-627.05K-1.83M-3.11M-1.44M-1.76M-2.38M-1.85M-1.84M-4.03M-31.75M8.09M-4.21M-2.34M-3.99M-2.34M-3.39M-3.60M--3.53M-4.08M-3.49M--2.23M-2.78M-2.87M-8.90M-9.60M
Diluted EPS ---------0.59---0.18---0.12-----0.67-0.66--4.100.42-12.96-5.77-4.10-8.13-7.93-7.38--4.59-3.32-2.32--0.47-0.58-0.38--0.05
R&D Expense 2.11M-3.18M3.31M3.39M-3.07M2.47M3.59M2.90M2.59M1.38M1.17M1.01M897.10K1.51M954.45K825.49K696.89K446.03K466.01K471.11K--------362.00K--16.00M-----6.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -733.44K390.62K407.71K110.00K18.83K10.42K16.25K260.00K260.00K15.39K13.52K-0250.00K00
Cost of Revenue -----------------
Gross Profit -----------------
Operating Expenses -------------15.31M13.10M14.86M18.06M
Operating Income -10.47M-15.18M-12.99M-10.16M-12.52M-17.44M-19.16M-20.64M-13.31M-8.26M-8.63M-9.30M--15.31M-12.85M-14.86M-18.06M
EBITDA --------------14.24M-12.28M-14.42M-16.77M
Interest Expense -------------13.00K15.00K12.00K10.00K
Pretax Income --------------14.26M-12.30M-14.44M-16.78M
Tax Provision -----------------
Net Income -10.36M-18.39M-12.52M-10.12M-19.83M-22.63M-20.90M-21.07M-15.67M-4.92M-8.35M-10.32M--14.26M-12.30M-14.44M-16.78M
Diluted EPS ------------3.72--247.95-27.01-10.19-0.30
R&D Expense 5.35M9.16M7.35M6.11M7.29M8.36M12.64M13.16M8.10M3.96M4.06M2.02M---16.00M-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --10.59M4.09M8.75M19.41M29.84M14.95M22.60M13.88M7.68M6.58M3.02M-15.76M14.05M10.88M134.34M
Current Assets --------------14.73M13.33M10.49M134.22M
Cash & Equivalents 4.90M2.31M9.26M2.35M7.44M16.85M12.52M4.72M15.19M6.67M5.79M5.11M713.00K-12.38M12.43M9.82M133.38M
Inventory ------------------
Receivables -------------0----
Total Liabilities --2.74M2.43M1.78M11.00M12.12M9.98M11.27M5.37M1.63M1.46M10.12M-3.28M2.74M3.39M4.96M
Current Liabilities --2.74M2.43M1.76M5.94M4.01M6.43M7.33M1.51M1.05M1.22M8.08M-3.01M2.59M3.24M4.64M
Long Term Debt ----04.93M8.06M3.38M----94.00K-----
Total Debt --------------404.00K369.00K169.00K71.00K
Total Equity -2.56M-5.02M7.85M1.66M6.97M8.42M17.72M4.97M11.33M8.52M6.05M-8.33M-16.60M-12.48M11.31M7.49M129.38M
Shares Outstanding --------------396.29K818.06K2.97M159.64M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.14M-9.98M-8.10M-8.48M----15.62M-13.42M-7.69M-7.26M-4.77M--13.36M-11.13M-12.19M-10.85M
Investing Cash Flow -210.78K-332.68K-480.85K-254.86K---2.36M-94.05K5.00M--6.00K-54.00K-10.00K-4.00K0-
Financing Cash Flow 2.76M17.27M1.67M13.82M---23.74M4.99M1.81M6.59M1.89M-15.26M11.19M9.58M134.44M
Capital Expenditure -88.38K-76.32K-196.41K-39.22K-125.36K-207.89K-176.27K-98.09K-11.40K-1.71K--6.00K--10.00K-4.00K--
Free Cash Flow -5.23M-10.06M-8.29M-8.52M----15.71M-13.43M-7.69M--4.77M--13.37M-11.14M-12.19M-10.85M
Net Change in Cash -------------1.89M49.00K-2.61M123.59M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % --2,070.4%-3,325.6%-2,491.1%-11,385.4%-92,581.4%-183,896.8%-127,027.2%-5,118.1%-3,176.7%-56,071.8%-68,764.8%---5,138.0%--
Net Margin % --2,507.0%-3,204.7%-2,482.5%-18,029.0%-120,154.7%-200,671.0%-129,721.8%-6,025.4%-1,894.1%-54,252.6%-76,346.2%---4,920.0%--
ROE % 206.6%-234.1%-754.2%-145.2%-235.6%-127.7%-420.8%-186.0%-184.0%-81.4%100.2%62.2%--114.3%-108.7%-192.7%-13.0%
ROCE % --193.3%-782.6%-145.2%-92.9%-67.5%-224.7%-135.1%-107.6%-124.5%-161.1%183.6%--120.1%-112.0%-194.4%-13.9%

Shareholding Pattern

Insiders
2.15%
Institutions
101.26%
Public Float
103.48%

Top Institutional Holders

#Holder% HeldSharesValue
1 Soleus Capital Management, L.P. 7.50% 13.06M $20.77M
2 B Group, Inc. 6.55% 11.41M $18.15M
3 Ameriprise Financial, Inc. 6.36% 11.08M $17.62M
4 Jupiter Topco LLC 6.13% 10.69M $17.00M
5 Blackrock Inc. 5.99% 10.44M $16.59M
6 Octagon Capital Advisors LP 5.90% 10.28M $16.34M
7 Perceptive Advisors Llc 4.83% 8.43M $13.40M
8 RA Capital Management, L.P. 4.09% 7.12M $11.33M
9 Franklin Resources, Inc. 3.32% 5.79M $9.20M
10 Point72 Asset Management, L.P. 3.01% 5.25M $8.35M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PALI

Google News hu, 03 Sep 2026

Three September healthcare conferences will include Palisade Bio management - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNM2JGam9aQklEeXlTOG1tRWg1bVFQN1Q5bFNoQ1JtTlNjck1EY0N4QlpoZ1FPWE41NUR3aG01NmlSelZRY3Y5SFo3ajZSNmk5VVFiSndhekp2WjFza0hMa09zdTcyWHNRRFVNVVBwU2dOclcxeEpuV1hSc0JJYmVZOEVzdGNjc0s3MjRuMW…

Google News Fri, 15 May 2026

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNbnB5a3V6SkxtWlozSlZad1ltRDJoUzZYcV82aXNoeG1td1o2YTRJTFhCQnV5VnJ3YkQ5Uk10ZXIzQVBJUkkxaHpnMlRsblRiTmxxZnBJeXZRU3ZNa0JocE5GeC1xbWZNcTl5YUZZTy1rLU1OT2wyWFNsRk1QTzV2WFY1ZzdBYUVNVXZxZl…

Google News Mon, 29 Jun 2026

$PALI stock is up 9% today. Here's what we see in our data. | PALI Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPUTkySDlkMEdsNy1DdXpEV0s5dnUwNjJkc2VVbVRPSWpJYzRWS3N3S3kzZHcwdE5IM1lpZXhRYllCdXZ1dDVCNmVyM29wXzhfUHAwdGVCWWR1NHlGUkJZd0szbjIyNnZEeWJsRlRqaDh1YmZKYjJ3ZmE3MUZ5Nmo0VXlqLXExMmVKaU9qSW…

Google News Sat, 30 May 2026

PALI - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE0tZjc0T1U0V1VZdXk3MkZFWDNwZW12eTlyUXI2LUFpdW1odFNjU3hpWXJJUjNaSk9JNHZxdWZId2c5ekJQVXc?oc=5" target="_blank">PALI</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News hu, 25 Jun 2026

PALI Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9FM3hEdjF5M2RfWkZBeHo0NTJlN2tCUVIxNFdIZkNHNFV1LUhNVzFicnhmZUFrQ1Q2R0FqbEtqTm42am9Ndm5JLUZ2T1o1dVBRYUFSN09oUlpJVUYtMGxVYVhMclhKUXU5YWdwRFpPSlBqb2N0dmo5Zzh3?oc=5" target="_blank">PAL…

Google News Mon, 29 Jun 2026

PALI Stock Climbs As Palisade Bio Loads Up Dealmakers - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5yNjM2VHFXblM4bDhSSWEtTk5sNUU1X3RhUEt2YXdXbXFUc3Mxa2YxWlpNMDBSSlVUVnUxalI4ZEJzRTdFMlB3UTB3aTA5S3Fkb1lBcHFsV284RjFYUWtyekNQd3FOQnhIRm1lcHZmNnBZcU9od0VhdA?oc=5" target="_blank">PALI …

PALI — Frequently Asked Questions

What is the current share price of Palisade Bio, Inc. (PALI)?

As of 2026-09-19 21:16 PDT, Palisade Bio, Inc. (PALI) trades at $2.20 on NasdaqCM. Its 52-week range is $0.54 to $2.80.

What is the market capitalisation of PALI?

Palisade Bio, Inc. (PALI) has a market capitalisation of $383.40M on NasdaqCM.

What is the P/E ratio of PALI?

PALI trades at a trailing price-to-earnings (P/E) ratio of 3.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.27.

What is the return on equity (ROE) of PALI?

PALI has a return on equity (ROE) of -51.37%. Its return on capital employed (ROCE) is -13.92%.

Is PALI a good stock to buy?

This page provides a data-driven analysis of Palisade Bio, Inc. (PALI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space